Abstract:Abstract Purpose: MicroRNAs (miRNA) can function as oncogenes or tumor suppressors. In this study, we test the hypothesis that genetic variation within miRNA processing genes or miRNA binding sites in cancer-related genes may alter clinical outcomes for non–small cell cancer (NSCLC) patients. Methods: We genotyped 72 single nucleotide polymorphisms (SNPs) from eight miRNA processing genes and 168 SNPs from 133 predicted miRNA binding sites in 535 patients with early stage (stages I, IIA, and IIB) NSCLC to determine the effect of these variations on progression risk and overall survival. We further conducted a subset analysis to exclude potential bias due to different treatment regimens. Results: In the analysis of overall survival, an FAS SNP remained significant for decreased risk after multiple comparisons in all early patients (HR: 0.59, 95% CI: 0.44–0.77; GG: MST = 58 mos, GA + AA: MST = 118 mos) and surgery plus chemotherapy subgroup (HR: 0.19, 95% CI: 0.07–0.46, P = 1.84 × 10−5; GG: MST = 65 mos, GA + AA: MST = 137 mos). In the surgery-only patients, an FZD4 SNP (HR: 0.46, 95% CI: 0.32–0.65; GG: MST = 59 mons, GA + AA: MST = 117 mos) had a significant protective effect after multiple comparisons adjustment. For progression risk, following multiple comparison, an SP1 SNP (HR: 2.19, 95% CI: 1.45–3.32; GG: MST > 270 mos, GA + AA: MST = 45 mos) and an MBD1 SNP (HR: 2.41, 95% CI: 1.45–4.0; AA: MST > 270 mos, C + CC: MST = 90 mos) remained significant increased progression risk in the entire and surgery only population respectively. All the associations significant after adjusting for multiple comparisons were validated by Bootstrap resampling method. A strong cumulative effect of these variant genotypes to increase risk and dramatically decrease median event-free time was consistently observed. We also identified potential higher-order gene–gene interactions among these SNPs. Conclusions: We identified significant association between miRNA-related genetic variants and early stage NSCLC patient clinical outcomes. With validation, our result can be used in the prognosis of clinical outcomes for early stage NSCLC patients.

Functional miRNA variants affect lung cancer susceptibility and platinum-based chemotherapy response.

Association of miR-605 and miR-149 genetic polymorphisms with related risk factors of lung cancer susceptibility]

Age-related Common Mirna Polymorphism Associated with Severe Toxicity in Lung Cancer Patients Treated with Platinum-Based Chemotherapy.

A Genetic Polymorphism In Pre-Mir-27a Confers Clinical Outcome Of Non-Small Cell Lung Cancer In A Chinese Population

Non-Coding RNA Polymorphisms (rs2910164 and rs1333049) Associated With Prognosis of Lung Cancer Under Platinum-Based Chemotherapy

Association of well-characterized lung cancer lncRNA polymorphisms with lung cancer susceptibility and platinum-based chemotherapy response

A Functional Genetic Variant in Microrna-196A2 is Associated with Increased Susceptibility of Lung Cancer in Chinese.

Hsa-miR-196a2 functional SNP is associated with severe toxicity after platinum-based chemotherapy of advanced nonsmall cell lung cancer patients in a Chinese population.

Sequence Variation in Mature MicroRNA-499 Confers Unfavorable Prognosis of Lung Cancer Patients Treated with Platinum-Based Chemotherapy.

Genetic variants in regulatory regions of microRNAs are associated with lung cancer risk.

Abstract A3: MicroRNA-related Polymorphisms Are Associated with Clinical Outcomes in Early Stage Non-Small Cell Lung Cancer Patients

Polymorphisms Of Microrna Sequences Or Binding Sites And Lung Cancer: A Meta-Analysis And Systematic Review

Genetic Polymorphism of SLC31A1 is Associated with Clinical Outcomes of Platinum-Based Chemotherapy in Non-Small-cell Lung Cancer Patients Through Modulating Microrna-Mediated Regulation.

Association Between Single Nucleotide Polymorphisms (Snps) And Toxicity Of Advanced Non-Small-Cell Lung Cancer Patients Treated With Chemotherapy

Associations Between Genetic Variants Located in Mature Micrornas and Risk of Lung Cancer

Effects of Four Single Nucleotide Polymorphisms in Microrna-Coding Genes on Lung Cancer Risk

Association between well-characterized lung cancer lncRNA polymorphisms and platinum-based chemotherapy toxicity in Chinese patients with lung cancer

A Functional Variant in Mir-155 Regulation Region Contributes to Lung Cancer Risk and Survival

MicroRNA-Related Genetic Variants As Predictors of Early Stage Non–Small Cell Lung Cancer Clinical Outcomes

Variations Within 3′-UTR of MDM4 Gene Contribute to Clinical Outcomes of Advanced Non-Small Cell Lung Cancer Patients Following Platinum-Based Chemotherapy

Association Between Two Genetic Variants in Mirna and Primary Liver Cancer Risk in the Chinese Population.